July 23, 2020 / 7:16 PM / 23 days ago

Moderna loses patent challenge against Arbutus vaccine technology

July 23 (Reuters) - Shares of Moderna Inc fell nearly 10% after the U.S. Patent Trial and Appeal Board determined that the company’s claims against Arbutus Biopharma’s vaccine technology patent were not valid.

Arbutus shares soared 56% after the patent board posted its opinion on its electronic docket.

Moderna did not immediately respond to a Reuters request for comment. (Reporting by Vishwadha Chander in Bengaluru; Editing by Anil D’Silva)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below